Chongqing Publicizes August Batch of Listed and Delisted Medical Insurance Drugs – Synchronized Database Removal Set as Appeal Window Opens

Leave a reply

Chongqing, China – 20 Sep 2026 – The Chongqing Municipal Healthcare Security Bureau publicized information on medical insurance drugs newly listed (挂网) and delisted (撤网) on the municipal procurement platform during August 2026, per the city’s drug trading and procurement listing rules. For the delisted products, the Bureau plans to simultaneously remove the relevant drug information from the medical insurance system database – a step that effectively ends reimbursement‑channel recognition of those SKUs. The publicity and online acceptance period runs from 20 to 22 September 2026, with real‑name written appeals accepted until the deadline.

Policy Snapshot

ItemDetail
AgencyChongqing Municipal Healthcare Security Bureau
DocumentPublicity of August 2026 Listed and Delisted Medical Insurance Drug Information
ScopeAnnex 1 – drugs listed (挂网) in Aug 2026; Annex 2 – drugs delisted (撤网) in Aug 2026
Follow‑On ActionDelisted products to be removed synchronously from the medical insurance system database
Publicity Period20–22 Sep 2026
Online Acceptance Period20–22 Sep 2026
Appeal RequirementsReal‑name written appeals with lawful, valid evidence and contact details, in both PDF and Word versions; late filings not accepted
Excluded AppealsThose lacking evidence or unrelated to drug medical insurance payment standards – in principle not accepted
OfficeRoom 615, Chongqing Municipal Healthcare Security Bureau, Zone B4, Mercury Technology Building, No. 5 Huangshan Avenue (Middle Section), Liangjiang New Area
ContactsTel: 023‑88979951 / 023‑88979969; Email: cqsybjyyfwglc@163.com (dedicated to this publicity only)

Listing & Delisting Mechanics

  • Monthly Transparency Cycle: The dual‑annex publicity covers the full August turnover of the platform – both newly listed medical insurance drugs and those withdrawn from listing – giving manufacturers, hospitals, and distributors a monthly checkpoint of catalog changes in one of China’s largest municipalities.
  • Database Synchronization: The planned concurrent deletion of delisted products from the medical insurance system database means the withdrawal is not merely a platform‑level change: reimbursement system recognition is revoked in step, tightening the link between procurement listing status and insurance payment eligibility.
  • Enterprise Responsibilities: The Bureau instructs affected enterprises to promptly coordinate with medical institutions on drug stocking and supply arrangements (药品配备), implying that hospitals should adjust formularies and inventories around the listed and delisted SKUs.
  • Strict Appeal Protocol: Appeals must be real‑name, written, evidence‑backed, and submitted in both PDF and Word formats before the deadline; the dedicated email address accepts only appeals related to this publicity, and filings without evidence or unrelated to medical insurance payment standards will in principle be rejected.

Market Impact & Outlook

  • Reimbursement Channel Discipline: Synchronizing delisting with database removal accelerates the exit of non‑compliant or commercially withdrawn products from Chongqing’s reimbursed drug channel, reinforcing the listing platform as the single source of truth for insurance‑payable drugs.
  • Compliance Clock: With publicity, online acceptance, and the appeal deadline all compressed into the three‑day window of 20–22 September, enterprises disputing a listing or delisting outcome must prepare complete evidence packages essentially in advance.
  • Payment‑Standard Focus: The Bureau’s explicit narrowing of acceptable appeals to matters related to drug medical insurance payment standards signals that challenges on other grounds – commercial, procedural, or otherwise – face a high admissibility bar.
  • Supply‑Chain Coordination: Hospitals and distributors should cross‑check the August annexes against formulary systems to ensure newly listed SKUs are orderable and delisted SKUs are removed from procurement workflows, minimizing dispensing and reimbursement disruptions.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization of August 2026 listing and delisting results, the synchronized removal of delisted drugs from the medical insurance system database, appeal outcomes, and related supply arrangements in Chongqing. Actual results may differ due to risks including appeal handling decisions, evidence sufficiency, and subsequent policy adjustments by the Chongqing Municipal Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://ylbzj.cq.gov.cn/zwgk_535/gstz/202609/t20260920_16107566.html

Shanghai Orders Procurement Suspension for Ganmao Qingre Tablets – Hebei Tangwei Product Halted from Midnight, 21 September

Leave a reply

Shanghai, China – 20 Sep 2026 – The Shanghai Medical Insurance Centralized Bidding and Procurement Administration Office announced that, pursuant to relevant directives of the National Healthcare Security Administration, the procurement qualification of one drug product – Ganmao Qingre Tablets (film‑coated), manufactured by Hebei Tangwei Pharmaceutical Co., Ltd. – will be suspended from 00:00 on 21 September 2026. The notice was addressed to all medical institutions and drug manufacturers participating in the city’s centralized procurement platform.

Policy Snapshot

ItemDetail
AgencyShanghai Medical Insurance Centralized Bidding and Procurement Administration Office
AuthorityRelevant document(s) of the National Healthcare Security Administration (specific document reference not disclosed)
MeasureSuspension of procurement qualification
Product Affected1 – Ganmao Qingre Tablets (film‑coated)
ManufacturerHebei Tangwei Pharmaceutical Co., Ltd.
Effective Time00:00, 21 Sep 2026
Suspension DurationNot disclosed
Reason for SuspensionNot disclosed in the notice body
Notice Date20 Sep 2026

Product Under Suspension

Generic NameDosage FormSpecificationUnitManufacturer
Ganmao Qingre Tablets (traditional Chinese medicine cold‑relief formula)Film‑coated tablet0.55 g per tablet × 32 tablets/box, aluminum‑plastic blister packagingBoxHebei Tangwei Pharmaceutical Co., Ltd.

Compliance Notes

  • Scope of Impact: With procurement qualification suspended, the affected Ganmao Qingre Tablets SKU cannot be purchased through Shanghai’s centralized procurement platform by medical institutions from the effective time – though the notice does not specify whether existing contracts or in‑transit orders are affected.
  • National‑Level Origin: The suspension is executed on the basis of a national directive rather than a Shanghai‑initiated review, indicating the underlying compliance issue originated at the National Healthcare Security Administration level and may extend to other provinces as they implement the same document.
  • Manufacturer Exposure: For Hebei Tangwei Pharmaceutical, the loss of procurement eligibility in Shanghai – one of China’s highest‑value pharmaceutical markets – removes a key public‑channel revenue line for the product until qualification is restored.
  • Restoration Pathway: The notice does not disclose the suspension’s duration, the specific grounds, or the procedure for reinstatement; affected enterprises will need to engage with the issuing authorities for remediation and restoration requirements.

Market Impact & Outlook

  • Enforcement Signal: The swift, midnight‑effective implementation underscores the increasingly automated and directive‑driven nature of China’s drug procurement credit management, where national‑level determinations translate directly into provincial platform actions.
  • TCM Procurement Discipline: The targeted product is a traditional Chinese medicine cold‑relief formula, extending procurement‑compliance enforcement into the TCM segment alongside chemical drugs and biologics.
  • Cross‑Province Watch: Because the action stems from a national directive, distributors and manufacturers should monitor whether other provincial procurement platforms issue matching suspension notices for the same product – a common pattern under China’s nationwide price‑and‑credit linkage mechanisms.
  • Immediate Action for Medical Institutions: Shanghai hospitals and clinics should remove the suspended SKU from ordering workflows effective 21 September to avoid transaction failures and compliance exposure.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the suspension of procurement qualification, potential restoration of trading eligibility, and related enforcement actions for Ganmao Qingre Tablets in Shanghai and other jurisdictions. Actual results may differ due to risks including undisclosed suspension grounds and duration, appeal or remediation outcomes, and subsequent policy actions by the National Healthcare Security Administration and the Shanghai Medical Insurance Centralized Bidding and Procurement Administration Office.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/09/20/24901.shtml

Yunnan Reclassifies Five Listed Drugs as Essential Medicines – Commitment‑Based Filing Opens as Attribute Changes Take Effect

Leave a reply

Kunming, China – 20 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center publicized a batch of drug attribute changes on the provincial procurement platform, reclassifying five products from non‑essential‑drug status to essential drug (including former provincial‑supplement items) under the National Essential Medicines List (2026 Edition) and the Yunnan Provincial Supplemental Drug Catalog. Affected manufacturers must complete notification‑and‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) effective immediately, while objections must be lodged within five working days of the publicity date.

Policy Snapshot

ItemDetail
AgencyYunnan Provincial Government Procurement and Transfer Center
DocumentPublicity of Drug Attribute Changes for Platform‑Traded Products (annexed Attribute Change Table)
BasisNational Essential Medicines List (2026 Edition); Yunnan Provincial Supplemental Drug Catalog
Products Affected5 – all reclassified from non‑essential drug to essential drug / former provincial supplement
Price & Registration ImpactApproval numbers unchanged; procurement price ceilings unchanged
Filing ObligationNotification‑and‑commitment filing with Yunnan MPA, effective from the publicity date
Objection Window5 working days from publicity (enterprises: 0871‑63606934, Drug & Device Procurement Section; public: 0871‑65330065, Comprehensive Supervision Section)
Filing VenueReception Hall, 1F, Yunnan Institute for Food and Drug Control and Testing – New Building, 616 Kefa Road, Kunming; Tel: 0871‑63112057

Products Reclassified

Product IDGeneric NameDosage FormSpecificationManufacturer / BidderNew Attribute
53521224Cefradine for InjectionInjection1.0 g (as C16H19N3O4S)Shaanxi Dunsi Pharmaceutical Co., Ltd.Former provincial supplement
53527176Inosine InjectionInjection2 ml : 0.1 gShaanxi Dunsi Pharmaceutical Co., Ltd. / Xi’an Tangchen Pharmaceutical Co., Ltd. (bidder)Former provincial supplement
53526685Pancreatin Enteric‑Coated TabletsEnteric‑coated tablet0.3 g × 24 tablets/boxChongqing Tianzhi Pharmaceutical Co., Ltd.Essential drug (NEML 2026)
53825865Pancreatin Enteric‑Coated TabletsEnteric‑coated tablet0.3 g × 48 tablets/boxChongqing Tianzhi Pharmaceutical Co., Ltd.Essential drug (NEML 2026)
53501920Longbishu TabletsSugar‑coated tablet0.3 g core weight × 18 tablets/boxQinhuangdao Da’en Pharmaceutical Co., Ltd.Essential drug (NEML 2026)

Compliance Obligations & Procedure

  • Notification‑and‑Commitment Filing: For products flagged “essential drug (incl. former provincial supplement)”, the filing process opens immediately. Enterprises must follow the requirements set out in the Yunnan MPA’s published announcement (mpa.yn.gov.cn, notice t20210917_1231876) and complete commitment‑based filing in person, bringing a printed copy of this publicity notice to the designated Yunnan MPA location.
  • Consequences of Non‑Filing: Enterprises that fail to complete the notification‑and‑commitment filing bear full responsibility for the consequences, per the notice – a clear signal that platform trading status may hinge on timely compliance.
  • Dual‑Track Objection Mechanism: Applicant enterprises with queries on the publicized information contact the Center’s Drug & Device Procurement Section (0871‑63606934); other enterprises or members of the public raising objections contact the Comprehensive Supervision Section (0871‑65330065) – both within five working days of the publicity date, with the publicized content open to general supervision.
  • Administrative Continuity: Because drug approval numbers and procurement price ceilings remain unchanged, the reclassification is an attribute‑level adjustment rather than a repricing event – preserving existing commercial terms while altering catalog status.

Market Impact & Outlook

  • NEML 2026 Alignment: Three of the five products (both Pancreatin SKUs and Longbishu Tablets) were upgraded directly under the National Essential Medicines List (2026 Edition), illustrating how provinces are synchronizing procurement‑platform attributes with the refreshed national catalog.
  • Essential‑Drug Advantage: Essential‑drug designation typically carries policy preference in procurement and clinical use at public medical institutions – a status upgrade that can broaden access for the affected manufacturers’ products in Yunnan.
  • Provincial‑Supplement Track: The two former provincial‑supplement items (Cefradine for Injection, Inosine Injection) reflect continued recognition of Yunnan’s supplemental catalog alongside the national list, per the notice’s stated basis.
  • Tight Compliance Clock: With filing open “effective immediately” and only five working days to lodge objections, manufacturers must act within the same week to secure catalog status and avoid jeopardizing platform trading eligibility.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing outcomes, objection handling, catalog status, and platform trading eligibility for the five reclassified drug products in Yunnan Province. Actual results may differ due to risks including filing completion status, objection decisions, and subsequent policy adjustments by the Yunnan Provincial Government Procurement and Transfer Center and the Yunnan Provincial Medical Products Administration.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27877&CatalogId=3